A recent study into patient preferences highlights the importance of systematic methodologies to ensure effective identification of important findings.
The two-year study was conducted by Myeloma UK and the National Institute for Health and Clinical Excellence (NICE) and aimed to quantify the factors influencing patients’ decision-making regarding new medicines.
Currently, patient preferences are elicited from expert patients partaking in appraisal meetings, however a lack of systematic methodology makes it hard to quantify their contributions.
This study used discrete choice experiments to quantify patient preferences, which was particularly useful when extremely different treatment options were being considered.
“This study examining the ways that patient preference data could be used in decisions about new medicines had three stages:
- The first was to look at the literature and current research activity relating to patient preferences
- Researchers then held a workshop with patients and family members to understand more about what aspects of patient experience should be considered by researchers and by NICE
- An evaluative workshop was then held with researchers, health care professionals, policy makers, and other charities to discuss findings of the study so far”
Of particular interest were the different treatment preferences for patients who had been living with a condition for a long time, as opposed to those recently diagnosed.
Myeloma UK has not announced any further studies into this topic, however NICE Scientific Advice has recently piloted a project whereby scientific advice was provided to a patient preference study.
For further information, see the Myeloma UK press release here.